OBI Pharma Announces Acquisition of TH-3424 from Threshold Pharmaceuticals

TAIPEI, Taiwan, June 1, 2017 /PRNewswire/ — OBI Pharma, Inc., a Taiwan biopharma company (TPex:4174), announced today an agreement with Threshold Pharmaceuticals, Inc. (THLD) to acquire TH-3424, a first-in-class novel small-molecule prodrug that selectively targets cancers overexpressing the enzyme aldo-keto reductase 1c3 (AKR1C3). The product will be renamed OBI-3424 effective immediately.